Drug Trial Radar · NCT07220603
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Dec 23, 2025
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- PepGen IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
Conditions
- Myotonic Dystrophy 1
Interventions
PGN-EDODM1Drug
Administered by intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability as assessed by number of participants with Adverse Events (AEs)Time frame: Baseline through Week 108
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CIUSSS du Saguenay-Lac-Saint-Jean
Saguenay, Canada · Recruiting
University of Calgary
Calgary, Alberta, Canada · Recruiting
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.